Relief from malignant hypertension by treatment with captopril in a patient on maintenance hemodialysis.
A patient with end-stage renal disease due to malignant hypertension is described. Hypertension was resistant to hemodialysis. The orally active inhibitor of angiotensin-converting enzyme captopril (SQ 14.255; 2-D-methyl-3-mercaptopropanoyl-L-protein) dramatically lowered the elevated blood pressure both under ambulatory and dialysis conditions. No side effects were observed after 6 months' treatment. The effect of captopril could be described as a "biochemical nephrectomy".
D000328:Adult; D002216:Captopril / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D011392:Proline / Q000031:analogs & derivatives*; D006435:Renal Dialysis; D012083:Renin / Q000097:blood
D011392:Proline; D002216:Captopril; D012083:Renin